KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Capital Expenditures (2016 - 2025)

Fulgent Genetics' Capital Expenditures history spans 10 years, with the latest figure at $5.0 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 31.82% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $22.6 million, down 44.01%, while the annual FY2025 figure was $22.6 million, 44.01% down from the prior year.
  • Capital Expenditures for Q4 2025 was $5.0 million at Fulgent Genetics, down from $6.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $31.8 million in Q3 2024 and bottomed at $727000.0 in Q2 2024.
  • The 5-year median for Capital Expenditures is $4.8 million (2022), against an average of $6.4 million.
  • The largest annual shift saw Capital Expenditures surged 1343.72% in 2021 before it crashed 94.01% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $6.0 million in 2021, then decreased by 21.08% to $4.7 million in 2022, then tumbled by 34.22% to $3.1 million in 2023, then increased by 21.64% to $3.8 million in 2024, then surged by 31.82% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Capital Expenditures are $5.0 million (Q4 2025), $6.0 million (Q3 2025), and $6.8 million (Q2 2025).